125 related articles for article (PubMed ID: 38929568)
1. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer.
Kınıkoğlu O; Odabas H; Altıntaş YE; Yıldız A; Çakan B; Akdağ G; Yıldırım S; Bal H; Kaya T; Tünbekici S; Işık D; Başoğlu T; Yıldırım ME; Turan N
Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929568
[No Abstract] [Full Text] [Related]
2. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
4. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment.
Watanuki R; Shimomura A; Yazaki S; Noda-Narita S; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Yonemori K; Tamura K
Medicine (Baltimore); 2020 Sep; 99(38):e22331. PubMed ID: 32957402
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.
Noda-Narita S; Shimomura A; Kawachi A; Sumiyoshi-Okuma H; Sudo K; Shimoi T; Noguchi E; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Breast Cancer; 2019 Jul; 26(4):492-498. PubMed ID: 30737616
[TBL] [Abstract][Full Text] [Related]
7. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
[TBL] [Abstract][Full Text] [Related]
9. Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
Migeotte A; Dufour V; van Maanen A; Berliere M; Canon JL; Taylor D; Duhoux FP
BMC Cancer; 2021 Nov; 21(1):1204. PubMed ID: 34763656
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot X; Burris H; Petersen JA; Stanzel S; Strasak A; Patre M; Ellis P
J Clin Oncol; 2017 Jan; 35(2):141-148. PubMed ID: 28056202
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.
Ciapponi A; Bardach A; Colaci C; Rodríguez Cairoli F; Argento F; Korbenfeld E; García Martí S
Rev Peru Med Exp Salud Publica; 2024 May; 41(1):7-18. PubMed ID: 38808848
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T
Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035
[TBL] [Abstract][Full Text] [Related]
16. Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study.
Yazaki S; Hashimoto J; Ogita S; Nakano E; Suzuki K; Yamauchi T
Anticancer Drugs; 2020 Oct; 31(9):973-978. PubMed ID: 32868644
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.
Cortés J; Diéras V; Lorenzen S; Montemurro F; Riera-Knorrenschild J; Thuss-Patience P; Allegrini G; De Laurentiis M; Lohrisch C; Oravcová E; Perez-Garcia JM; Ricci F; Sakaeva D; Serpanchy R; Šufliarský J; Vidal M; Irahara N; Wohlfarth C; Aout M; Gelmon K
JAMA Oncol; 2020 Aug; 6(8):1203-1209. PubMed ID: 32584367
[TBL] [Abstract][Full Text] [Related]
18. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
Montemurro F; Ellis P; Anton A; Wuerstlein R; Delaloge S; Bonneterre J; Quenel-Tueux N; Linn SC; Irahara N; Donica M; Lindegger N; Barrios CH
Eur J Cancer; 2019 Mar; 109():92-102. PubMed ID: 30708264
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
